surmount-1 tirzepatide weight loss results reduction over time in tirzepatide‐treated participants by early weight response: Post hoc analysis in SURMOUNT‐1 - Ard - 2025 - Diabetes, Obesity and Metabolism Lilly orforglipron oral GLP-1 phase
Description
Wadden TA, et al
The meaningful companions are behavioral rather than pharmacological: Adequate protein intake because appetite drops sharply, protecting lean mass through deliberate protein consumption is the practical priority
Clinical trials demonstrated that patients who followed gradual escalation experienced significantly fewer gastrointestinal side effects compared to those on faster schedules
While increased urination is not listed as a direct adverse effect in the FDA prescribing information, several factors may explain why some patients report urinating more frequently while taking this medication
